This Article Full Text Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lemström, K. B. Articles by Koskinen, P. K. Search for Related Content PubMed PubMed Citation Articles by Lemström, K. B. Articles by Koskinen, P. K.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1996;16:553-564.)
© 1996 American Heart Association, Inc.

Articles

Triple Drug Immunosuppression Significantly Reduces Aortic Allograft Arteriosclerosis in the Rat

Karl B. Lemström; Anne K. Räisänen-Sokolowski; Pekka J. Häyry; Petri K. Koskinen

From the Transplantation Laboratory, University of Helsinki, and Helsinki University Central Hospital, Helsinki, Finland.

Correspondence to Petri Koskinen, MD, PhD, Transplantation Laboratory, PO Box 21 (Haartmaninkatu 3), FIN-00014 University of Helsinki, Finland.

Abstract We evaluated the effect of triple drug immunosuppression (cyclosporine A 10 mg·kg^-1·d^-1, methylprednisolone 0.5 mg·kg^-1·d^-1, and azathioprine 2 mg·kg^-1·d^-1) on the development of allograft arteriosclerosis (chronic rejection). The recipients of rat aortic allografts from the DA (AG-B4, RT1^a) to the WF (AG-B2, RT1^u) strain were either treated with triple drug immunosuppression (n=23) or left untreated (n=23) and used as controls. The grafts were removed 7, 14, 30, 90, and 180 days after transplantation, and vascular wall changes were evaluated by quantitative histology, [³H]thymidine autoradiography, and immunohistochemistry. Nonimmunosuppressed aortic allografts developed progressive arteriosclerotic alterations 1 to 6 months after transplantation that were virtually identical to those observed during chronic rejection in human cardiac allografts. Linear regression analysis revealed that triple drug immunosuppression with clinically relevant dosages of drugs significantly reduced intimal thickening (r=.69 versus r=.88, P<.05). Concomitantly, there was a marked reduction in the number of inflammatory cells (P<.01) and their rate of proliferation (P<.025) in the allograft adventitia during the period of acute inflammation (30 days after transplantation). Immunohistochemistry revealed that the number of helper T cells (W3/25) and monocyte/macrophages (OX42) but not cytotoxic T cells (OX8) or natural killer cells (3.2.3) was significantly (P<.05) reduced. The number of adventitial cells expressing interleukin-2 receptor (CD25) (P<.05), MHC class II (OX6) (P<.05), and leukocyte function–associated antigen–1 -chain (CD11a) (P<.025) was also significantly reduced at 30 days. Triple drug immunosuppression downregulated the induction of MHC class II and intercellular adhesion molecule–1 on the graft endothelium but had no significant effect on the number of subendothelial inflammatory cells. In addition, [³H]thymidine autoradiography demonstrated that triple drug immunosuppression significantly reduced the rate of cell proliferation in the media, composed of smooth muscle cells, 30 and 90 days after transplantation. Thus, triple drug immunosuppression efficiently reduced the development of allograft arteriosclerosis by downregulating the inflammatory response and the level of immune activation in the allograft adventitia during the acute rejection period, resulting in diminished intimal thickening of the graft in the long run. These results support the concept that allograft arteriosclerosis is due to or at least initiated by immune injury of the graft.

Key Words: cyclosporine • allograft • arteriosclerosis • chronic rejection • rat

This article has been cited by other articles:

				L. Liu, A. M. Garcia, H. Santoro, Y. Zhang, K. McDonnell, J. Dumont, and A. Bitonti Amelioration of Experimental Autoimmune Myasthenia Gravis in Rats by Neonatal FcR Blockade J. Immunol., April 15, 2007; 178(8): 5390 - 5398. [Abstract] [Full Text] [PDF]

				K. B. Lemstrom, R. Krebs, A. I. Nykanen, J. M. Tikkanen, R. K. Sihvola, E. M. Aaltola, P. J. Hayry, J. Wood, K. Alitalo, S. Yla-Herttuala, et al. Vascular Endothelial Growth Factor Enhances Cardiac Allograft Arteriosclerosis Circulation, May 28, 2002; 105(21): 2524 - 2530. [Abstract] [Full Text] [PDF]

				S. Sartore, A. Chiavegato, E. Faggin, R. Franch, M. Puato, S. Ausoni, and P. Pauletto Contribution of Adventitial Fibroblasts to Neointima Formation and Vascular Remodeling: From Innocent Bystander to Active Participant Circ. Res., December 7, 2001; 89(12): 1111 - 1121. [Abstract] [Full Text] [PDF]

				M. S. Eisenberg, H. J. Chen, M. K. Warshofsky, R. R. Sciacca, H. S. Wasserman, A. Schwartz, and L. E. Rabbani Elevated Levels of Plasma C-Reactive Protein Are Associated With Decreased Graft Survival in Cardiac Transplant Recipients Circulation, October 24, 2000; 102(17): 2100 - 2104. [Abstract] [Full Text] [PDF]

				T. Matsumura, K. Kugiyama, S. Sugiyama, Y. Ota, H. Doi, N. Ogata, H. Oka, and H. Yasue Suppression of Atherosclerotic Development in Watanabe Heritable Hyperlipidemic Rabbits Treated With an Oral Antiallergic Drug, Tranilast Circulation, February 23, 1999; 99(7): 919 - 924. [Abstract] [Full Text] [PDF]